Where Will Vertex Pharmaceuticals Be in 1 Year?
Vertex Pharmaceuticals (NASDAQ: VRTX) has significantly underperformed broader equities over the past 12 months, with its shares down 10% since March of 2025, compared to a 15% gain for the S 500. However, ongoing developments suggest that the biotech leader could be staging a rebound, and if it does, now might be a great time to buy the stock. Let's see how things could unfold for Vertex Pharmaceuticals in the next year.
Image source: Getty Images.
Vertex Pharmaceuticals makes most of its money from the sale of medicines for cystic fibrosis (CF), a rare disease that affects the lungs and other organs and causes difficulty breathing. Vertex Pharmaceuticals' most important therapies for CF are Trikafta, which treats up to 90% of CF patients, and the newer Alyftrek, which offers the added benefit of once-daily dosing.
Source Fool.com
Vertex Pharmaceuticals Inc. Aktie
Einseitige Meinung: Vertex Pharmaceuticals Inc. erhält nur Buy-Einschätzungen und keine Sell-Einschätzungen.
Das von der Community festgelegte Kursziel von 461 € für Vertex Pharmaceuticals Inc. bedeutet eine mögliche Steigerung um über 20% im Vergleich zu 374.9 €.
